Catalog Products » Other Products » New Products » GFAP Antibody, mAb, Mouse
Email to GenScript

GFAP Antibody, mAb, Mouse


*This product has been discontinued! *


Abbreviated name-1 Mouse Anti-GFAP mAb; Anti GFAP (monoclonal)
Description Glial fibrillary acidic protein (GFAP) is a member of the class III intermediate filament protein family. It is heavily, and specifically, expressed in astrocytes and certain other astroglia in the central nervous system, in satellite cells in peripheral ganglia, and in non myelinating Schwann cells in peripheral nerves. In addition, neural stem cells frequently strongly express GFAP. Antibodies to GFAP are therefore very useful as markers of astrocytic cells. In addition many types of brain tumor, presumably derived from astrocytic cells, heavily express GFAP. GFAP is also found in the lens epithelium, Kupffer cells of the liver, in some cells in salivary tumors and has been reported in erythrocytes.
Immunogen Purified pig spinal core GFAP
Host Species Mouse
Conjugation Unconjugated
Purification Method Immunoaffinity purification

Formulation 1 mg/ml in PBS, pH 7.4 with 0.05% sodium azide, frozen liquid
Clone ID A00085.01
Ig Subclass Mouse Monoclonal (IgG1)
Specificity Mouse Anti GFAP is known to react with human, cow, pig, mouse, rat and all other mammalian and avian species tested to date.
Storage Stable for 1 year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing. Aliquot will be stable at 4°C for 3 months.
Note Briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container's cap because small volumes of antibody will occasionally become entrapped in the seal of the product vial during shipment and storage.

Western blot at dilutions of 1:1,000 and Immunofluorescence experiments at 1:100 dilutions respectively. It is very useful as a loading control for quantitative Western blotting.


Chekhonin VP, et al. Monoclonal anti-GFAP antibodies: extraction, characteristics, and immunoenzyme assay. Bull Exp. Biol. Med. Aug 2001; 132(2): 772-775.

You can visit "Citations Database" for more citations. Poletaev AB, et al. Serum anti-S100b, anti-GFAP and anti-NGF autoantibodies of IgG class in healthy persons and patients with mental and neurological disorders. Autoimmunity. 2000; 32(1): 33-38.

You can visit "Citations Database" for more citations. Mecocci P, et al. Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia. J. Neuroimmunol. Mar 1995; 57(1-2): 165-170.

You can visit "Citations Database" for more citations. Vacca V.,et al. Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and μ opioid receptor expression in neuropathic mice.Brain Behav Immun.2013Feb;

You can visit "Citations Database" for more citations. Marinelli S.,et al. The Analgesic Effect on Neuropathic Pain of Retrogradely Transported botulinum Neurotoxin A Involves Schwann Cells and Astrocytes.PLoS One.2012Otc;7(10):e47977

You can visit "Citations Database" for more citations.






For more documents, please visit "Technical Support".